| Bioactivity | Retagliptin phosphate (SP2086 phosphate) is a selective, competitive and orally active dipeptidyl peptidase-4 (DPP-4) inhibitor. Retagliptin phosphate can be used for type 2 diabetes mellitus (T2DM) research[1]. |
| Target | DPP-4. |
| Invitro | Retagliptin is a class of compound used for research of type 2 diabetes. Retagliptin inhibits the degradation of GLP-1, thus amplifying the incretin effect[1]. |
| Name | Retagliptin phosphate |
| CAS | 1256756-88-3 |
| Formula | C19H21F6N4O7P |
| Molar Mass | 562.36 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
| Reference | [1]. Hu C, et al. Pharmacokinetics of Phosphate Retagliptin Tabletin in Patients with Renal Dysfunction. Sichuan Da Xue Xue Bao Yi Xue Ban. 2018 Jan;49(1):74-80. [2]. Avivit Cahn, et al. An update on DPP-4 inhibitors in the management of type 2 diabetes. Expert Opin Emerg Drugs. 2016 Dec;21(4):409-419. |
Retagliptin phosphate
CAS: 1256756-88-3 F: C19H21F6N4O7P W: 562.36
Retagliptin phosphate (SP2086 phosphate) is a selective, competitive and orally active dipeptidyl peptidase-4 (DPP-4) in
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.